Document is current
Any future updates will be listed below
-
Authors
Verkerk, K. https://orcid.org/0000-0002-5882-4980
Spiekman, A. C.
Haj Mohammad, S. F.
Verbeek, F. A. J.
Timmer, H. https://orcid.org/0009-0002-3822-7326
van Maren, M. A. https://orcid.org/0009-0009-8799-4821
Zeverijn, L. J.
Geurts, B. S.
van der Noort, V. https://orcid.org/0000-0002-4910-4535
Roepman, P.
Jansen, A. M. L.
de Leng, W. W. J.
Gelderblom, H. https://orcid.org/0000-0001-9270-8636
Verheul, H. M. W.
Voest, E. E. https://orcid.org/0000-0001-8249-9586
,
Nienhuis, H. H.
van Dodewaard-de Jong, J. M.
Labots, M.
de Groot, D. J. A.
van Herpen, C.
Hoeben, A.
Gelderblom, H.
Beerepoot, L. V.
Kerver, E. D.
Westgeest, H. M.
Bins, A. D.
Hamberg, A. P.
Boon, E.
Vreugdenhil, G.
de Klerk, G. J.
van Voorthuizen, T.
Vulink, A.
van den Berkmortel, F.
van Rooijen, M.
Houtsma, D.
Imholz, A. L. T.
van den Berg, H. P.
Douma, J. A. J.
de Mol, P.
Hovenga, S.
Hendriks, M. P.
de Groot, J. W. B.
Los, M.
Boudewijns, S.
Klein Hesselink, E. N.
Siemerink, E.
Tromp, S. C. S.
Davidis-van Schoonhoven, M. A.
Jeurissen, F.
- License Information
-
More Information
Article History
Received: 2 September 2025
Accepted: 11 March 2026
First Online: 15 April 2026
Competing interests
: H.G. is a board member of the Center for Personalized Cancer Treatment, coordinator of PCM4EU, co-coordinator of PRIME-ROSE and a member of the advisory committee of health care reimbursement (ACP) of Zorginstituut Nederland. E.E.V. is founder and current member of the supervisory board of the Hartwig Medical Foundation, independent non-executive director and shareholder of Sanofi, co-founder and shareholder of Mosaic Therapeutics and a board member and founder of the Center for Personalized Cancer Treatment. E.E.V. has received clinical study grants from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Clovis, Eisai, Eli Lilly, GSK, Ipsen, Johnson & Johnson, MSD, Novartis, Pfizer, Roche and Sanofi, all paid to the Netherlands Cancer Institute. The other authors declare no competing interests.
